Latest News

Keep up to date with all our latest investments, service offerings and news items.

• December 4, 2024

  Almac announces key partnership with Future Medicines Institute

• May 30, 2024

  Almac Discovery nominates ALM-401 as a First in Class Bispecific Next Generation ADC targeting EGFR/ROR1 to progress into pre-clinical development

• November 29, 2023

  Almac Discovery and Queen’s University launch state-of-the-art Chemoproteomics facility in Belfast

• June 6, 2023

  WEE1 Inhibitor discovered by Almac Discovery advanced into two clinical studies addressing the treatment of advanced solid tumours 

• August 24, 2022

  Almac Discovered Molecule Progresses into Clinical Development with its strategic licensee Vaderis Therapeutics AG

• June 1, 2022

  Almac Discovery nominates a first candidate molecule from its Protein Drug Conjugate (PDC) Platform to progress into pre-clinical development

• May 20, 2022

  Almac Discovery and HitGen Announce Strategic Research Collaboration

• December 16, 2021

  Debiopharm Further Explores the Potential of Potent, Highly Selective WEE1 Inhibitor in Phase 1 Cancer Study

• July 20, 2021

  Almac Discovery Expands Disease Focus into Respiratory Disease

• May 18, 2021

  Almac Discovery Publishes Ground-breaking Cancer Research

• January 18, 2021

  Professor Daniel Longley Joins Almac Discovery to Accelerate Colorectal Cancer Research

• June 18, 2020

  Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

• May 14, 2020

  Almac Discovery Enters Into Licensing Agreement for the Development & Commercialisation of ALM301

• April 29, 2020

  Almac Discovery to Collaborate with MSD on selected DUB therapeutic targets

• March 5, 2020

  Debiopharm Advances its Potent Wee1 Inhibitor into Clinical Phase

• October 1, 2019

  Almac Group Appoints Dr Alan Lamont as VP BD & Licensing

• March 20, 2019

  Almac Discovery and Elasmogen to Share Anti-ROR-1 VNAR Data at American Association of Cancer Annual Meeting

• March 18, 2019

  Almac Discovery Showcases its Deubiquitinase Drug Discovery Expertise at the American Association of Cancer Research Annual Meeting in Atlanta

• August 6, 2018

  VNAR Based Oncology Platform in development

• July 5, 2018

  Dr. Xavier Jacq Appointed Vice President, Biology

• April 23, 2018

  Latest developments in DUB inhibitors shared at Proteasome & Autophagy Congress

• April 10, 2018

  Almac Discovery to Present at AACR 2018

• January 29, 2018

  Research Highlighted in Nature Chemical Biology

• December 4, 2017

  USP7 inhibitors from UbiPlexTM Platform published

• September 4, 2017

  ALM201 Poster Presentation at 2017 ESMO Congress

• July 3, 2017

  ALM201 – Orphan Drug Designation Granted in Ovarian Cancer

• June 20, 2017

  Agreement with Debiopharm to Develop Novel Wee-1 Inhibitor

• May 8, 2017

  Wee-1 kinase patent approval granted

• February 14, 2017

  Therapy-resistant cancer tumours targeted with RCSI

• May 30, 2016

  Diseases of the eye explored with McClay Foundation and UU

• October 5, 2015

  European Patent Protection for ALM201 Secured

• July 10, 2015

  Ubiquitin Specific Protease Collaboration with Genentech

• September 4, 2013

  £13m Investment Cancer Research Initiatives with QUB

• April 27, 2009

  Minister Praises Craigavon Life Sciences Firm’s Commitment to R&D

• June 10, 2008

  Almac Group Launches Oncology Discovery Arm